Natures Sunshine Products Inc

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.natr.com
  • Earnings Score
  • Moat Score
  • Market Cap $229.37M
  • PE 30
  • Debt -
  • Cash $84.70M
  • EV -
  • FCF $14.33M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$7.70M
EBIT$20.10M
ROE5%
ROA8%
FCF$14.33M
Equity$160.99M
Growth Stability-2%
PE29.8
PEG-3.07
PB1.42
P/FCF16.01
P/S0.5
Price/Cash0.37
Net Margins2%
Gross Margins71%
Op. Margins4%
Earnings CAGR12%
Sales Growth YoY9%
Sales Growth QoQ3%
Sales CAGR8%
FCF CAGR15%
Equity CAGR3%
Earnings Stability0.05
Earnings Growth YoY-104%
Earnings Growth QoQ-107%
Earnings CAGR 5Y-10%
Sales CAGR 5Y4%
FCF CAGR 5Y-9%
Equity CAGR 5Y3%
Earnings CAGR 3Y1%
Sales CAGR 3Y1%
FCF CAGR 3Y30%
Equity CAGR 3Y5%
Market Cap$229.37M
Revenue$454.36M
Assets$240.86M
Cash$84.70M
Shares Outstanding18.48M
Earnings Score7%
Moat Score67%
Working Capital94.89M
Current Ratio2.44
Gross Profit$324.69M
Shares Growth 3y-2%
Equity Growth QoQ-1%
Equity Growth YoY1%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Natures Sunshine Products Inc is a natural health and wellness company, primarily engaged in the manufacturing and selling of nutritional and personal care products. The company markets its products in Australia, Austria, Belarus, Canada, Colombia, Costa Rica, the Czech Republic, Denmark, the Dominican Republic, Ecuador, El Salvador, Finland, Germany, Guatemala, Honduras, Hong Kong, and in various other countries. The company operates in four segments namely, Asia, Europe, North America, and Others. It offers products related to general health, immunity, cardiovascular, digestive, personal care and weight management.

SEC Filings

Direct access to Natures Sunshine Products Inc (NATR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Natures Sunshine Products Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Natures Sunshine Products Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 12%
Stability 5%
loading chart...

Natures Sunshine Products Inc Discounted Cash Flow

Fully customizable DCF calculator online for Natures Sunshine Products Inc.

= $402M
012345678910TV
fcf$14M$16M$19M$22M$25M$29M$33M$38M$43M$50M$57M$569M
DCF$15M$16M$16M$17M$18M$19M$19M$20M$21M$22M$219M
Value$402M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years09/201512/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins--4%-0%2%6%6%-0%3%2%2%
ROA-2%3%8%9%13%7%8%8%8%
ROE--12%-1%5%14%18%-0%9%5%5%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years09/201512/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-2.62-00.150.13-0.340--
Debt over Equity-0.11-00.030.020.020--
Growth Stability-----100%-2%91%53%-2%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years09/201512/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--7%-1%6%15%-5%6%2%4%
Earnings YoY growth---91%-663%215%35%-101%-4K%-49%-10%
Equity YoY growth--1%7%21%3%-9%8%1%3%
FCF YoY growth--238%-85%1K%-15%-125%-544%-53%-9%